BioPharma Dive
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma s interest in new and emerging oral therapies for hereditary angioedema.
BioPharma Dive
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma s interest in new and emerging oral therapies for hereditary angioedema.
BioPharma Dive
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma s interest in new and emerging oral therapies for hereditary angioedema.